| 3.315 0.065 (2%) | 01-30 15:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.26 | 1-year : | 4.97 |
| Resists | First : | 3.65 | Second : | 4.26 |
| Pivot price | 3.02  |
|||
| Supports | First : | 2.54 | Second : | 1.87 |
| MAs | MA(5) : | 3.36 |
MA(20) : | 2.8 |
| MA(100) : | 6.9 |
MA(250) : | 5.5 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 77.7 |
D(3) : | 82.5 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 11.45 | Low : | 1.07 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RZLT ] has closed below upper band by 30.3%. Bollinger Bands are 57.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.5 - 3.52 | 3.52 - 3.54 |
| Low: | 3.19 - 3.21 | 3.21 - 3.23 |
| Close: | 3.22 - 3.25 | 3.25 - 3.28 |
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Tue, 27 Jan 2026
SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - TMX Newsfile
Sun, 25 Jan 2026
Faruqi & Faruqi Encourages Rezolute Investors to Discuss Legal Options - Intellectia AI
Thu, 22 Jan 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc. - RZLT - PR Newswire
Wed, 14 Jan 2026
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating - PR Newswire
Thu, 18 Dec 2025
Rezolute: Phase 3 sunRIZE Data For Ersodetug Warrants Downgrade To Sell Rating (RZLT) - Seeking Alpha
Mon, 15 Dec 2025
Down 81.8% in 4 Weeks, Here's Why Rezolute (RZLT) Looks Ripe for a Turnaround - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 93 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 10.5 (%) |
| Held by Institutions | 110.6 (%) |
| Shares Short | 12,910 (K) |
| Shares Short P.Month | 10,480 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.62 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.7 % |
| Return on Equity (ttm) | -59.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.9 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -70 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -3.52 |
| PEG Ratio | 0 |
| Price to Book value | 2.04 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |